to Notification of Missing Requirements.

| U.S. APPLICATION NO. (If kn | | R. 1.5) | INTERNATIONAL APPLICAT | | TA | | TTORNEY'S DOCKET NUMBER | | |
|--|------------------|---------------|--|---------------------------------------|--------------|-------------|----------------------------------|--|-----------|
| 10/088,6 | | ttod. | PCT/IT00/00373 | · · · · · · · · · · · · · · · · · · · | | | 4161-2 CALCULATIONS PTO USE ONL | | LICE ONLY |
| 21. The following fees are submitted: BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5): | | | | | 1 6 | ALCULATIONS | FIC | USE ONLY | |
| Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1040.00 | | | | | | | | | |
| International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$890.00 | | | | | | | | | |
| International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO\$740.00 | | | | | | | | | |
| International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) | | | | | | | | | |
| International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)\$100.00 | | | | | L | | | | |
| | | | ENTER APPROPRIATE | | AMOUNT = | \$ | 0.00 | | |
| Surcharge of \$130.00 fo months from the earliest | | | eclaration later than 20 | □ 30 | | s | 0.00 | | |
| CLAIMS | NUMBE | | NUMBER EXTRA | B | ATE | 1 | 0.00 | | |
| Total Claims | 53 | -20 = | 33 | X | \$18.00 | \$ | 594.00 | <u> </u> | |
| Independent Claims | 6 | -3 = | 3 | X | \$84.00 | Ť | 252.00 | | |
| MULTIPLE DEPENDEN | T CLAIMS(S) | (if applicabl | e) | \$28 | 30.00 | \$ | 280.00 | | |
| | | | TOTAL OF AB | OVE CALC | II ATIONS - | \$ | 1126.00 | | |
| Applicant claims sr | nall entity sta | tus. See 37 | CFR 1.27. The fees indica | | JLATIONS = | 3 | 1126.00 | | |
| are reduced by 1/2 | | | | | | | 563.00 | | |
| D | 20 6 6 | · | | | UBTOTAL = | \$ | 563.00 | | |
| months from the earliest | | | ish Translation later than [C.F.B. 1.492(f)). | _ 20 | | | 0.00 | | |
| | | | Т | | ONAL FEE = | \$ | 563.00 | - | |
| | | | F.R. 1.21(h)). The assignr c.F.R. 3.28, 3.31). \$40.00 | | + | \$ | 40.00 | | |
| | | | n (\$400 – Small Entity = \$2 | | | \$ | 200.00 | | |
| | | · | | | NCLOSED = | \$ | 803.00 | | |
| | | | | | | Α | mount to be: | | |
| | | | | | | ├ | refunded Charged | \$ \$ | |
| | | , | | | | _ | Charged | Þ | |
| a. \(\) A check in the amount of \$803.00 to cover the above fees is enclosed. b. \(\) Please charge my Deposit Account No. 14-1140 in the amount of \$\) to cover the above fees. A duplicate copy of this form is enclosed. c. \(\) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed. d. \(\) The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application. | | | | | | | | | |
| NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status. | | | | | | | | | |
| SEND ALL CORRESPO | NDENCE TO | D: | | SIGNATI | Cup C | Cuf | | <u>. </u> | |
| NIXON & VANDERHYE | | | | SIGNATI | JIT. | | | | |
| 1100 North Glebe Road Arlington, Virginia 22201 | | | | | | | | | |
| Telephone: (703) 816-40 | | | | Arthur | R. Crawf rd | | | | |
| ARC:eaw | | | | NAME | | | | | |
| 3/2002 GFREY1 00000061 | 10088678 | | | 05.00- | | | | | |
| C:: 2615 | 297.00 | <u>OP</u> | | 25,327 BEGIST | RATION NUMBI | FR | October 16 Date | , 20 |)2 |
| -0:2614 | 126.00 140.00 | . | · · · · · · · · · · · · · · · · · · · | TILOIOT | | -:- | Date | | |
| FC:2616 | 200.00 | ŎP | | | | | | | |



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#6

In re Patent Application of

TATO, F

Atty. Ref.: 4161-2

Serial No. 10/088,678

Group:

Filed: March 21, 2002

Examiner:

For: METHOD FOR THE SELECTIVE PROTECTION OF PROLIFERATING

NORMAL CELLS AND THE SELECTIVE ERADICATION OF TUMOR CELLS

HAVING AN INACTIVE P53 PATHWAY

: * * * * * * * * *

October 16, 2002

Assistant Commissioner for Patents Washington, DC 20231

Sir:

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Responsive to the Notice to File Missing Requirements dated June 18, 2002, petition is hereby made for a two month extension of time for which our check in the appropriate amount is attached.

Attached is a declaration from the inventors in compliance with 37 CFR §1.497(a) and (b).

The Notice to Filing Missing Parts also indicated that nucleotide and/or amino acid sequence disclosures were noted in the application and therefore a "Sequence Listing" is required. With respect, this is not the case – there are no nucleotide and/or amino acid sequence contained in the disclosure of this application. Perhaps there was some confusion associated with applicants' frequent use of abbreviations instead of repeating lengthy names and terms. As an illustration of this page 12, line 10 combined treatment (CT) is mentioned and later in the specification the abbreviation is used as on

** TATO,.F Serial No. 10/088,678

page 18, line 7. Another of the many instances is on page 42 where mouse embryofibroblast (MEF) cells are mentioned.

As there is no disclosure of nucleotides and/or amino acid sequence in the application as filed, no sequence listing is required nor appropriate.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Arthur R! Crawford Reg. No. 25,327

ARC:eaw 1100 North Glebe Road, 8th Floor Arlington, VA 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

4161-2 ARC

DT19 Rec'd PCT/PTO

1 6 OCT 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

Construction of the Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 2023

| U.S. APPLICATION NUMBER NO. | FIRST NAMED APPLICANT | ATT | ATTY. DOCKET NO. | | |
|------------------------------------|-----------------------|------------------|------------------|--|--|
| 10/088,678 | F Tato 4161 | | 4161-2 | | |
| | INTERNATIONAL AF | | PLICATION NO. | | |
| A.D | | PCT/IT00/ | PCT/IT00/00373 | | |
| Nixon & Vanderhye | | I.A. FILING DATE | PRIORITY DATE | | |
| 1100 North Glebe Road 8th Floor | | 09/21/2000 | 09/21/1999 | | |

CONFIRMATION NO. 4826
371 FORMALITIES LETTER
OC000000008295620

Date Mailed: 06/18/2002

Arlington, VA 22201-4714

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Request for Immediate Examination

DOCKETED

| CLT/MATTER # 461 | -2 | |
|-------------------|------|------|
| MAIL DATE (elista | | |
| DUE DATE Aug | 18: | 2002 |
| FINAL DEADLINEJan | 18 | 2003 |
| DOCKETED BY MYS | az Z | |

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

 Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Additionally the following defects have been observed:

The following items MUST be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
 - Additional claim fees of \$568 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$568 for a Large Entity:

- Total additional claim fee(s) for this application is \$568
 - \$288 for 16 total claims over 20.
 - \$280 for multiple dependant claims surcharge.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

| | | ······································ |
|-----------------------------|-------------------------------|--|
| U.S. APPLICATION NUMBER NO. | INTERNATIONAL APPLICATION NO. | ATTY. DOCKET NO. |
| 10/088,678 | PCT/IT00/00373 | 4161-2 |



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

TATO, F

Atty. Ref.: 4161-2

Serial No. 10/088,678

Group:

Filed: March 21, 2002

Examiner:

For: METHOD FOR THE SELECTIVE PROTECTION OF PROLIFERATING NORMAL CELLS AND THE SELECTIVE ERADICATION OF TUMOR CELLS HAVING AN

INACTIVE P53 PATHWAY

October 16, 2002

Assistant Commissioner for Patents Washington, DC 20231

Sir:

SUBMISSION OF INVENTORS' DECLARATION UNDER 37 C.F.R. §1.42 AND 1.63

Attached is a declaration signed by the three heirs of Franco TATO, deceased, together with proof of authority in the form of a Declaration Substitutive of a Notority Deed (in Italian) including a verified English translation of same.

The declaration is also executed by inventors Antonio ZANETTI and Milena GROSSI.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Arthur R/Crawford

Reg. No. 25,327

ARC:eaw

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100